Here, we proposed a simple score based on WT1 expression levels, NBC by flow cytometry, and FLT3 mutational status for risk stratification of AML patients, while WT1 expression levels and NBC might identify a subgroup of MDS patients with poorer prognosis. The gene discussed is WT1; the disease is myelodysplastic syndrome.